{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:32Z","timestamp":1792787252612,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771678"],"award-info":[{"award-number":["81771678"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["YN2019QN02"],"award-info":[{"award-number":["YN2019QN02"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Greater Bay Area Research Institute of Precision Medicine","award":["I0005"],"award-info":[{"award-number":["I0005"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1136\/ard-2022-223736","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T13:20:27Z","timestamp":1675171227000},"page":"688-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis"],"prefix":"10.1016","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct04047576","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-9767","authenticated-orcid":false,"given":"Hui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8152-2489","authenticated-orcid":false,"given":"Cuiping","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223736_bib1","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2015101110","article-title":"Idiopathic retroperitoneal fibrosis","volume":"27","author":"Vaglio","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard-2022-223736_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MD.0b013e3181afc420","article-title":"Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation","volume":"88","author":"van Bommel","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223736_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223736_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/iju.14218","article-title":"Current approach to diagnosis and management of retroperitoneal fibrosis","volume":"27","author":"Tanaka","year":"2020","journal-title":"Int J Urol"},{"key":"10.1136\/ard-2022-223736_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/art.21698","article-title":"Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin","volume":"55","author":"Martorana","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223736_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/M13-2648","article-title":"Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study","volume":"161","author":"Goldoni","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223736_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223736_bib8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"10.1136\/ard-2022-223736_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223736_bib10","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls. Treasure Island (FL), 2022."},{"key":"10.1136\/ard-2022-223736_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10157-019-01759-w","article-title":"Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis","volume":"23","author":"Moriconi","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1136\/ard-2022-223736_bib12","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.ajkd.2019.04.020","article-title":"Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse","volume":"74","author":"Raffiotta","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/ard-2022-223736_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/03009742.2018.1497700","article-title":"Long-Term outcomes and predictors of a large cohort of idiopathic retroperitoneal fibrosis patients: a retrospective study","volume":"48","author":"Zhao","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223736_bib14","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/jcm10071380","article-title":"Characteristics of adult patients with idiopathic retroperitoneal fibrosis and assessment of risk of relapse at diagnosis","volume":"10","author":"Razanamahery","year":"2021","journal-title":"J Clin Med"},{"key":"10.1136\/ard-2022-223736_bib15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ard-2022-223736_bib16","doi-asserted-by":"crossref","first-page":"D877","DOI":"10.1093\/nar\/gkw1012","article-title":"MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search","volume":"45","author":"Rappaport","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2022-223736_bib17","first-page":"D845","article-title":"The disgenet knowledge platform for disease genomics: 2019 update","volume":"48","author":"Pi\u00f1ero","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2022-223736_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpbi.5","article-title":"The genecards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1136\/ard-2022-223736_bib19","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2022-223736_bib20","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the drugbank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2022-223736_bib21","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The chembl database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1136\/ard-2022-223736_bib22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223736_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/08916934.2019.1693545","article-title":"Th1, Th2, and Th17 cytokines in systemic lupus erythematosus","volume":"53","author":"Muhammad Yusoff","year":"2020","journal-title":"Autoimmunity"},{"key":"10.1136\/ard-2022-223736_bib24","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex pea immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ard-2022-223736_bib25","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.2174\/092986709788803042","article-title":"The effects of tamoxifen on immunity","volume":"16","author":"Behjati","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1136\/ard-2022-223736_bib26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","article-title":"Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis","volume":"72","author":"Alberici","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223736_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2011-200148","article-title":"Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis","volume":"71","author":"Binder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223736_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-154-1-201101040-00005","article-title":"Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series","volume":"154","author":"Scheel","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223736_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/annrheumdis-2019-216258","article-title":"Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients","volume":"79","author":"Urban","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223736_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1432-2277.2004.00070.x","article-title":"Efficacy of rapamycin in patient with juvenile rheumatoid arthritis","volume":"18","author":"Foroncewicz","year":"2005","journal-title":"Transpl Int"},{"key":"10.1136\/ard-2022-223736_bib31","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223736_bib32","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223736_bib33","doi-asserted-by":"crossref","first-page":"857424","DOI":"10.3389\/fimmu.2022.857424","article-title":"Sirolimus monotherapy for thrombocytopenia in primary antiphospholipid syndrome: a pilot study from a tertiary referral center","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223736_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jconrel.2013.07.016","article-title":"A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in A mouse model of sj\u00f6gren's syndrome","volume":"171","author":"Shah","year":"2013","journal-title":"J Control Release"},{"key":"10.1136\/ard-2022-223736_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1136\/ard-2022-223736corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:36:01Z","timestamp":1739504161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724084681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003496724084681"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223736","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.05.22279516","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}